ES2070519T3 - Proceso para la sintesis de (4r-cis)-1,1-dimetiletil-6-cianometil-2,2-dimetil-1,3-dioxano-4-acetato. - Google Patents

Proceso para la sintesis de (4r-cis)-1,1-dimetiletil-6-cianometil-2,2-dimetil-1,3-dioxano-4-acetato.

Info

Publication number
ES2070519T3
ES2070519T3 ES91919118T ES91919118T ES2070519T3 ES 2070519 T3 ES2070519 T3 ES 2070519T3 ES 91919118 T ES91919118 T ES 91919118T ES 91919118 T ES91919118 T ES 91919118T ES 2070519 T3 ES2070519 T3 ES 2070519T3
Authority
ES
Spain
Prior art keywords
cis
dimetiletil
cianometil
dimetil
dioxano
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES91919118T
Other languages
English (en)
Inventor
Alan Millar
Donald Eugene Butler
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Warner Lambert Co LLC
Original Assignee
Warner Lambert Co LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co LLC filed Critical Warner Lambert Co LLC
Application granted granted Critical
Publication of ES2070519T3 publication Critical patent/ES2070519T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D319/00—Heterocyclic compounds containing six-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D319/04—1,3-Dioxanes; Hydrogenated 1,3-dioxanes
    • C07D319/06—1,3-Dioxanes; Hydrogenated 1,3-dioxanes not condensed with other rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
  • Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)

Abstract

SE DESCRIBE UN PROCESO PARA LA PREPARACION DE COMPUESTO DE LA FORMULA (I) QUE COMPRENDE EL TRATAMIENTO DE FORMA QUIMICA DE UN COMPONENTE DE LA FORMULA (V) DONDE L ES HALOGENO O (ALFA), DONDE AR ES ARIL, CON UN COMPUESTO DE LA FORMULA (VI)): M CN. UN SEGUNDO ASPECTO DE LA PRESENTE INVENCION ES UN NUEVO PRODUCTO INTERMEDIO DE LA FORMULA (V).
ES91919118T 1990-10-17 1991-09-11 Proceso para la sintesis de (4r-cis)-1,1-dimetiletil-6-cianometil-2,2-dimetil-1,3-dioxano-4-acetato. Expired - Lifetime ES2070519T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/599,521 US5103024A (en) 1990-10-17 1990-10-17 Process for the synthesis of (4r-cis)-1,1-dimethylethyl 6-cyanomethyl-2,2-dimethyl-1,3-dioxane-4-acetate

Publications (1)

Publication Number Publication Date
ES2070519T3 true ES2070519T3 (es) 1995-06-01

Family

ID=24399962

Family Applications (1)

Application Number Title Priority Date Filing Date
ES91919118T Expired - Lifetime ES2070519T3 (es) 1990-10-17 1991-09-11 Proceso para la sintesis de (4r-cis)-1,1-dimetiletil-6-cianometil-2,2-dimetil-1,3-dioxano-4-acetato.

Country Status (20)

Country Link
US (1) US5103024A (es)
EP (1) EP0553213B1 (es)
JP (1) JP3105923B2 (es)
KR (1) KR0166385B1 (es)
AT (1) ATE118772T1 (es)
AU (1) AU646311B2 (es)
CA (1) CA2092997C (es)
CZ (5) CZ282992B6 (es)
DE (1) DE69107622T2 (es)
DK (1) DK0553213T3 (es)
ES (1) ES2070519T3 (es)
FI (1) FI108539B (es)
HK (1) HK1005026A1 (es)
HU (2) HU213731B (es)
IE (1) IE62940B1 (es)
NO (1) NO301588B1 (es)
PT (1) PT99244B (es)
RU (1) RU2067580C1 (es)
SK (5) SK280938B6 (es)
WO (1) WO1992006968A1 (es)

Families Citing this family (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5245047A (en) * 1988-02-22 1993-09-14 Warner-Lambert Company Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis
US5149837A (en) * 1988-02-22 1992-09-22 Warner-Lambert Company Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis
US5298627A (en) * 1993-03-03 1994-03-29 Warner-Lambert Company Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis
HRP960312B1 (en) 1995-07-17 2001-10-31 Warner Lambert Co NOVEL PROCESS FOR THE PRODUCTION OF AMORPHOUS /R-(R*, R*)/-2-(4-FLUOROPHENYL)-"beta", "delta"-DIHYDROXY-5-PHENYL-4-/(PHENYLAMINO)CARBONYL/-1H-PYRROLE -1-HEPTANOIC ACID CALCIUM SALT (2 : 1)
US6087511A (en) * 1996-07-16 2000-07-11 Warner-Lambert Company Process for the production of amorphous [R-(R*,R*)]-2-(4-fluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl )-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid) calcium salt (2:1)
CA2329893A1 (en) * 1998-04-30 1999-11-11 Kaneka Corporation Process for producing 6-cyanomethyl-1,3-dioxane-4-acetic acid derivatives
HU227840B1 (en) * 1999-05-06 2012-05-02 Egis Gyogyszergyar Nyilvanosan M Kod Ruszvunytarsasag Intermediates of atorvastatin synthesis and process for producing them
IN191236B (es) 1999-05-25 2003-10-11 Ranbaxy Lab Ltd
US20040063969A1 (en) * 1999-10-18 2004-04-01 Egis Gyogyszergyar Rt. Process for the preparation of amorphous atorvastatin calcium
MXPA02004078A (es) 1999-12-17 2002-10-11 Warner Lambert Res & Dev Un proceso a escala industrial para producir sal de hemi calcio de trihidrato de atorvastatin cristalino.
CA2391357C (en) * 1999-12-17 2009-01-06 Warner Lambert Research And Development Ireland Limited A process for producing crystalline atorvastatin calcium
US7521216B2 (en) 1999-12-29 2009-04-21 Verenium Corporation Nitrilases and methods for making and using them
US7608445B1 (en) 1999-12-29 2009-10-27 Verenium Corporation Nitrilases, nucleic acids encoding them and methods for making and using them
US7300775B2 (en) 1999-12-29 2007-11-27 Verenium Corporation Methods for producing α-substituted carboxylic acids using nitrilases and strecker reagents
US20040014195A1 (en) * 1999-12-29 2004-01-22 Diversa Corporation Nitrilases, nucleic acids encoding them and methods for making and using them
JP3844112B2 (ja) 2000-08-23 2006-11-08 高砂香料工業株式会社 ３，５，６−トリヒドロキシヘキサン酸アンモニウム塩誘導体、及びその製造方法
US6476235B2 (en) 2001-01-09 2002-11-05 Warner-Lambert Company Process for the synthesis of 5-(4-fluorophenyl)-1-[2-((2R,4R)-4-hydroxy-6-oxo-tetrahydro-pyran-2-yl)-ethyl]-2-isopropyl-4-phenyl-1H-pyrrole-3-carboxylic acid phenylamide
EP1724256A3 (en) 2001-01-09 2007-03-21 Warner-Lambert Company LLC Novel process for the synthesis of 5-(4-fluorphenyl)-1-2(2-((2r,4r)-4-hydroxy-6-oxo-tetrahydro-pyran-2-yl)-ethyl)-2-isopropyl-4-phenyl-1h-pyrrole-3-carboxylic acid phenylamide
WO2002057229A1 (en) * 2001-01-19 2002-07-25 Biocon India Limited FORM V CRYSTALLINE [R-(R*,R*)]-2-(4-FLUOROPHENYL)-ß,$G(D)-DIHYDROXY-5-(1-METHYLETHYL)-3-PHENYL-4-[(PHENYLAMINO)CARBONYL]-1H-PYRROLE-1- HEPTANOIC ACID HEMI CALCIUM SALT. (ATORVASTATIN)
SI20814A (sl) * 2001-01-23 2002-08-31 LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d. Priprava amorfnega atorvastatina
SI20848A (sl) 2001-03-14 2002-10-31 Lek, Tovarna Farmacevtskih In Kemijskih Izdelkov, D.D. Farmacevtska formulacija, ki vsebuje atorvastatin kalcij
PL367943A1 (en) 2001-06-29 2005-03-07 Warner-Lambert Company Llc Crystalline forms of 'r-(r*,r*)!-2-(4-fluorophenyl)-beta, delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-'phenylamino)carbonyl!-1h-pyrrole-1-heptanoic acid calcium salt (2:1) (atorvastatin)
GB0116212D0 (en) * 2001-07-03 2001-08-29 Avecia Ltd Process
EP2292600A1 (en) 2001-07-30 2011-03-09 Dr. Reddy's Laboratories Ltd. Crystaline forms VI and VII of atorvastatin calcium
PE20030324A1 (es) * 2001-07-31 2003-04-03 Warner Lambert Co Composiciones farmaceuticas de amlodipina y atorvastatina
US7563911B2 (en) * 2001-08-31 2009-07-21 Morepen Laboratories Ltd. Process for the preparation of amorphous atorvastin calcium salt (2:1)
HU227124B1 (en) * 2001-09-14 2010-07-28 Egis Gyogyszergyar Nyilvanosan Polymorphs of 1-pyrrole derivative, intermediate for the preparation of atorvastatin
UA77990C2 (en) * 2001-12-12 2007-02-15 Crystalline calcium salt of (2:1) [r-(r*,r*)]-2-(4-fluorophenyl)-?,?-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1h-pyrroleheptanic acid
CZ296967B6 (cs) 2002-02-01 2006-08-16 Zentiva, A.S. Zpusob výroby amorfní formy hemivápenaté soli (3R,5R) 7-[3-fenyl-4-fenylkarbamoyl-2-(4-fluorfenyl)-5-isopropylpyrrol-1-yl]-3,5-dihydroxyheptanové kyseliny (atorvastatinu)
DE10212492B4 (de) * 2002-03-21 2012-02-02 Daimler Ag Kolbenpumpe
AU2003251523A1 (en) * 2002-06-13 2003-12-31 Diversa Corporation Processes for making (r)-ethyl 4-cyano-3-hydroxybutyric acid
CA2494269A1 (en) * 2002-08-06 2004-02-19 Warner-Lambert Company Llc Process for preparing 5-(4-fluorophenyl)-1-[2-((2r,4r)-4-hydroxy -6-oxo-tetrahydro-pyran-2-yl)ethyl]-2-isopropyl-4-phenyl-1h-pyrrole-3-carboxylic acid phenylamide
US20060122403A1 (en) * 2002-09-03 2006-06-08 Sanjay Suri Atorvastatin calcium form vi or hydrates thereof
KR100529703B1 (ko) * 2002-09-23 2005-11-17 임광민 키랄 중간체의 제조방법 및 그를 이용한 아토바스타틴의제조방법
HRP20020885B1 (en) * 2002-11-11 2007-05-31 GlaxoSmithKline istra�iva�ki centar Zagreb d.o.o. SUBSTITUTED 9a-N-{N'-[4-(SULFONYL)PHENYLCARBAMOYL]}DERIVATIVES 9-DEOXO-9-DIHYDRO-9a-AZA-9a-HOMOERITHROMYCIN A AND 5-O-DESOZAMINYL-9-DEOXO-9-DIHYDRO-9a-AZA-9a-HOMOERITHRONOLIDE A
WO2004089894A1 (en) * 2003-04-14 2004-10-21 Warner-Lambert Company Llc Process for preparing 5-(4-fluorophenyl)-1-[2-((2r,4r)-4-hydroxy-6-oxo-tetrahydro-pyran-2-yl)ethyl]-2-isopropyl-4-phenyl-1h-pyrrole-3-carboxylic acid phenylamide
US20050182125A1 (en) * 2003-05-16 2005-08-18 Ambit Biosciences Corporation Pyrrole compounds and uses thereof
US20040248972A1 (en) * 2003-05-16 2004-12-09 Ambit Biosciences Corporation Compounds and uses thereof
JP2007500219A (ja) * 2003-05-16 2007-01-11 アンビット バイオサイエンシス コーポレーション 複素環化合物およびその使用法
US7790197B2 (en) * 2003-06-09 2010-09-07 Warner-Lambert Company Llc Pharmaceutical compositions of atorvastatin
US20050271717A1 (en) * 2003-06-12 2005-12-08 Alfred Berchielli Pharmaceutical compositions of atorvastatin
US20040253305A1 (en) * 2003-06-12 2004-12-16 Luner Paul E. Pharmaceutical compositions of atorvastatin
US7655692B2 (en) * 2003-06-12 2010-02-02 Pfizer Inc. Process for forming amorphous atorvastatin
WO2005012246A1 (en) * 2003-07-25 2005-02-10 Avecia Pharmaceuticals Limited Process and intermediate compounds useful in the preparation of statins, particularly atorvastatin
CN101318923A (zh) * 2003-09-17 2008-12-10 沃尼尔·朗伯有限责任公司 [R－(R*,R*)]－2－(4－氟苯基)－β,δ－二羟基－5－(1－甲基乙基)－3－苯基－4－[(苯基氨基)羰基]－1H－吡咯－1－庚酸的结晶形式
CA2456430A1 (en) * 2004-01-28 2005-07-28 Brantford Chemicals Inc. Improved process for the preparation of amorphous atorvastatin calcium
EP1577297A1 (en) 2004-03-17 2005-09-21 Ranbaxy Laboratories, Ltd. Process for the production of atorvastatin calcium in amorphous form
JP2007532622A (ja) * 2004-04-16 2007-11-15 ファイザー・プロダクツ・インク 非晶質アトルバスタチン・カルシウムの形成方法
US7875731B2 (en) 2004-05-05 2011-01-25 Pfizer Inc. Salt forms of [R-(R*,R*)]-2-(4-fluorophenyl)-β, δ-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)Carbonyl]-1H-pyrrole-1-heptanoic acid
CA2573969C (en) * 2004-07-16 2014-02-04 Lek Pharmaceuticals D.D. Oxidative degradation products of atorvastatin calcium
CA2672554C (en) 2004-07-20 2012-01-03 Warner-Lambert Company Llc Novel forms of [r-(r*,r*)]-2-(4-fluorophenyl).beta.,.delta.-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1h-pyrrole-1-heptanoic acid calcium salt (2:1)
US7645888B2 (en) * 2004-08-27 2010-01-12 Biocon Limited Process for the production of amorphous atorvastatin calcium
BRPI0519996A2 (pt) 2004-10-28 2009-04-07 Warner Lambert Co processo para formar atorvastatina amorfa
US20090208539A1 (en) * 2004-11-22 2009-08-20 Adel Penhasi Stable atorvastatin formulations
US20090088465A1 (en) * 2004-12-02 2009-04-02 Stephen Craig Dyar Pharmaceutical Compositions of Amorphous Atorvastatin and Process for Preparing Same
EP1922301A1 (en) * 2005-09-09 2008-05-21 Pfizer Science and Technology Ireland Limited Preparation of an atorvastatin intermediate
DE602005014686D1 (de) * 2005-09-09 2009-07-09 Pfizer Science & Tech Ltd Herstellung eines atorvastatin-zwischenprodukts
US20090216029A1 (en) * 2005-09-16 2009-08-27 Yatendra Kumar Process for the production of atorvastatin calcium in amorphous form
CA2547216A1 (en) 2005-09-21 2007-03-21 Renuka D. Reddy Process for annealing amorphous atorvastatin
ES2304335T3 (es) 2005-11-21 2010-05-19 Warner-Lambert Company Llc Formas nuevas del acido (r-(r*,r*))-2-(4-fluorofenil)-b,b-dihidroxi-5-(1-metiletil)-3-fenil-4-((fenilamino)carbonil)1h-pirrol-1-heptanoico, de magnesio.
EP1810667A1 (en) 2006-01-20 2007-07-25 KRKA, tovarna zdravil, d.d., Novo mesto Pharmaceutical composition comprising amorphous atorvastatin
WO2008053312A2 (en) * 2006-11-02 2008-05-08 Cadila Pharmaceuticals Limited Process for preparing amorphous atorvastatin hemi calcium salt and its intermediate
US7834195B2 (en) * 2007-01-24 2010-11-16 Apotex Pharmachem Inc. Atorvastatin calcium propylene glycol solvates
DK2115153T3 (da) 2007-03-01 2013-09-08 Bp Corp North America Inc Nitrilaser, nucleinsyrer som koder for dem og fremgangsmåder til at fremstille og anvende disse
US20110142883A1 (en) * 2007-07-20 2011-06-16 Actavis Group Ptc Ehf Amorphous Coprecipitates of Atorvastatin Pharmaceutically Acceptable Salts
EP2075246A1 (en) 2007-12-27 2009-07-01 M. J. Institute of Research A process for preparation of amorphous form of atorvastatin hemi-calcium salt
US8115015B2 (en) * 2009-01-26 2012-02-14 Cadila Healthcare Limited Process for the preparation of amorphous atorvastatin calcium
EP2614057B1 (en) * 2010-09-09 2015-10-21 DSM Sinochem Pharmaceuticals Netherlands B.V. Salts of 7-amino-3,5-dihydroxyheptanoic acid esters
WO2013004591A1 (en) 2011-07-01 2013-01-10 Dsm Sinochem Pharmaceuticals Netherlands B.V. Micronized crystals of atorvastatin hemicalcium
WO2016056031A1 (en) 2014-10-08 2016-04-14 Council Of Scientific & Industrial Research Novel diol compounds synthesis and its use for formal synthesis of (2r, 3 s)-3-hydroxypipecolic acid
CN106008251A (zh) * 2016-05-19 2016-10-12 河南豫辰药业股份有限公司 一种2-苯甲撑-3-氧代-4-甲基-n-苯基戊酰胺的制备方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4647576A (en) * 1984-09-24 1987-03-03 Warner-Lambert Company Trans-6-[2-(substitutedpyrrol-1-yl)alkyl]-pyran-2-one inhibitors of cholesterol synthesis
US4681893A (en) * 1986-05-30 1987-07-21 Warner-Lambert Company Trans-6-[2-(3- or 4-carboxamido-substituted pyrrol-1-yl)alkyl]-4-hydroxypyran-2-one inhibitors of cholesterol synthesis
US5003080A (en) * 1988-02-22 1991-03-26 Warner-Lambert Company Process for trans-6-(2-(substituted-pyrrol-1-yl)alkyl)pryan-2-one inhibitors of cholesterol synthesis
US5093363A (en) * 1989-08-22 1992-03-03 Shionogi & Co., Ltd. 2,4,6-substituted phenol derivatives
DE3929913A1 (de) * 1989-09-08 1991-04-04 Hoechst Ag 4-hydroxytetrahydropyran-2-one sowie die entsprechenden dihydroxycarbonsaeurederivate, salze und ester, verfahren zu ihrer herstellung, ihre verwendung als arzneimittel, pharmazeutische praeparate sowie vorprodukte

Also Published As

Publication number Publication date
CZ124597A3 (en) 1997-12-17
FI931680A (fi) 1993-04-14
HU219237B (en) 2001-03-28
IE913629A1 (en) 1992-04-22
NO301588B1 (no) 1997-11-17
IE62940B1 (en) 1995-03-08
SK280938B6 (sk) 2000-09-12
AU8848091A (en) 1992-05-20
NO931421D0 (no) 1993-04-16
CZ61493A3 (en) 1994-02-16
JP3105923B2 (ja) 2000-11-06
WO1992006968A1 (en) 1992-04-30
HUT64049A (en) 1993-11-29
EP0553213B1 (en) 1995-02-22
CZ282993B6 (cs) 1997-12-17
SK280940B6 (sk) 2000-09-12
EP0553213A1 (en) 1993-08-04
NO931421L (no) 1993-06-16
HU9701183D0 (en) 1997-09-29
JPH06502162A (ja) 1994-03-10
KR0166385B1 (en) 1999-01-15
HU9301122D0 (en) 1993-08-30
US5103024A (en) 1992-04-07
FI108539B (fi) 2002-02-15
CZ124797A3 (en) 1997-12-17
DE69107622D1 (de) 1995-03-30
PT99244B (pt) 1999-04-30
CZ282992B6 (cs) 1997-12-17
CZ209495A3 (en) 1997-12-17
HU213731B (en) 1997-09-29
PT99244A (pt) 1992-09-30
CA2092997A1 (en) 1992-04-18
CZ282922B6 (cs) 1997-11-12
AU646311B2 (en) 1994-02-17
DK0553213T3 (da) 1995-07-17
SK280941B6 (sk) 2000-09-12
SK280939B6 (sk) 2000-09-12
SK33993A3 (en) 1993-10-06
FI931680A0 (fi) 1993-04-14
CA2092997C (en) 2002-05-14
SK280942B6 (sk) 2000-09-12
HK1005026A1 (en) 1998-12-18
CZ124697A3 (en) 1997-12-17
DE69107622T2 (de) 1995-07-06
RU2067580C1 (ru) 1996-10-10
ATE118772T1 (de) 1995-03-15
CZ282994B6 (cs) 1997-12-17
KR930702328A (ko) 1993-09-08
CZ283003B6 (cs) 1997-12-17

Similar Documents

Publication Publication Date Title
ES2070519T3 (es) Proceso para la sintesis de (4r-cis)-1,1-dimetiletil-6-cianometil-2,2-dimetil-1,3-dioxano-4-acetato.
ES2103751T3 (es) Procedimiento para la obtencion de oxetanonas.
ES2089416T3 (es) Procedimiento de produccion de intermedios para uso en la produccion de alcoxiiminoacetamidas.
SE8001339L (sv) Antihyperkolesteraemiskt medel, monakolin k och framstellning derav
IE801884L (en) Preparation of 1ó-hydroxyvitamin d compounds from¹1ó-hydroxy-3,5-cyclovitamin d compounds
AR006058A1 (es) Procedimientos para preparar compuestos de dicianoacetato y de 1,2-pirazol-5-amino-3-substituido
DK32684A (da) Fremgangsmaade til fremstilling af 26,26,26,27,27,27-hexafluor-1alfa,25-dihydroxycholesterol og mellemprodukter til brug herfor
FR2654102B1 (fr) Procede de synthese de derives polyazotes cycliques.
ES2065446T3 (es) Proceso para la preparacion de amino-compuestos ciclicos con actividad anticonvulsiva.
ES2128332T3 (es) Metodo para la produccion de la 2-amino-6-halogenopurina y sintesis de un intermediario.
NO994049L (no) Metode for aa fremstille farmasöytiske forbindelser
GR1001125B (el) Μεθοδος δια την εις βιομηχανικη κλιμακα παραγωγην της βμυ 21502.
MX9302313A (es) Procedimiento para la obtencion de hexafluorclorobutenos.
ATE138903T1 (de) Verfahren zur herstellung von substituierten vinylbenzolen
ES2018764A4 (es) Procedimiento para la obtencion de alquildietanolamidas grasas purificadas, los productos obtenidos y sus usos.
ATE62243T1 (de) Verfahren zur herstellung eines optisch aktiven lactons und neue zwischenprodukte in diesem verfahren.
JPS55139330A (en) Camphoren derivative,perfume composition containing said derivative, and preparation of said derivative
ES2084084T3 (es) Procedimiento para la preparacion de derivados de ciclopropanonitrilo.
MX9605277A (es) Procedimiento para obtener carboxilatos croman.
MX9202347A (es) Proceso para la preparacion de intermediarios para obtener nizatidina y producto obtenido a partir de dicho proceso.
TH1208A (es)
FR2705959B1 (fr) Procédé de synthèse stéréospécifique de leucotriène B4 sous sa configuration 6Z, 8E, 10E et produits intermédiaires.
JPS55102533A (en) 1-substituted ethyl-2-methyl(1,2,6,7,8,8a-hexahydro) naphthalene derivative

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 553213

Country of ref document: ES